Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology | Family Medicine

Clinical Trials: Colorectal Cancer


A listing of clinical trials currently looking for volunteers to enroll in Colorectal Cancer studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : Birmingham Hematology and Oncology

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Birmingham : University of Alabama Birmingham Comprehensive Cancer Center

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Birmingham : Birmingham Hematology and Oncology Associates, LLC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Birmingham : Achieve Clinical Research LLC

Head to Head Study Epi proColon and FIT

Birmingham :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Arizona

Gilbert : Banner MD Anderson Cancer Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Glendale : Arizona Center for Cancer Care

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Glendale : Arizona Center for Cancer Care

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Glendale : Arizona Center for Cancer Care

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Hot Springs : Genesis Cancer Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

View More »

Scottsdale : Pinnacle Oncology Hematology

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Sedona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tucson : Arizona Clinical Research Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tucson : Visions Clinical Research

Head to Head Study Epi proColon and FIT

Arkansas

Bentonville : Highlands Oncology Group

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Fayetteville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Jonesboro : NEA Baptist Clinic

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Little Rock :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

California

Escondido : Southwest Cancer Care

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Monterey : Monterey Bay Oncology

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Oxnard : Ventura County Hematology Oncology Specialists

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Alhambra : Central Hematology Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Anaheim : Pacific Cancer Medical Center, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Anaheim : Pacific Medical Center

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Bakersfield : Comprehensive Blood and Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Bakersfield : Comprehensive Blood and Cancer Center

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Bellflower :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Burbank : Providence St. Joseph Medical Center-Disney Family Cancer Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Burbank : East Valley Hematology and Oncology Medical Center

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Burbank : Providence St. Joseph Medical Center

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Corona : Wilshire Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Duarte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Duarte : City of Hope Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fountain Valley : Compassionate Cancer Care Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Fountain Valley :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fresno :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Fresno : California Cancer Associates for Research and Excellence

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Fullerton : Saint Jude Heritage Healthcare

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Fullerton : St. Jude Heritage Healthcare

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Gilroy : Ronald H. Yanagihara, MD

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Glendale : White Memorial Medical Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Greenbrae : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Hayward :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

La Jolla : UCSD Moores Cancer Center

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

La Jolla, : University of California San Diego

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Laguna Hills : South Orange County Surgical Medical Group

Head to Head Study Epi proColon and FIT

Long Beach : Pacific Shores Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Los Angeles : Comprehensive Hematology Oncology Centers, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Los Angeles : UCLA Community Oncology Practice

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Los Angeles : Healthcare Partners Medical Group

Head to Head Study Epi proColon and FIT

Los Angeles : USC Norris Comprehensive Cancer Center

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Los Angeles :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Northridge : The Thomas and Dorothy Leavey Cancer Center Northridge Hospital Medical Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Oakland : Hematology Oncology Associates

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Oakland :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Oceanside : North County Oncology Medical Clinical Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Orange : UC Irvine Medical Center, Division of Hematology/Oncology

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Orange : Hematology Oncology Medical Group of Orange County

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Palo Alto : Stanford University Medical Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Pomona : Wilshire Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Rancho Cucamonga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Redondo Beach : Cancer Care Associates Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Redondo Beach : Pacific Shores Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Roseville :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Sacramento :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

San Diego : Sharp Health Care

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

San Diego : Sharp Memorial Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

San Francisco :

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

San Francisco : CPMCRI / Pacific Hematology Oncology Associates

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

San Francisco :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

San Francisco : Pacific Hematology Oncology Associates

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

San Jose : San Jose Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

San Jose :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

San Jose : San Jose Medical Group

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

San Luis Obispo : Coastal Integrative Cancer Care

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Santa Clara :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Santa Maria : Central Coast Medical Oncology Corp

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

South San Francisco :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Vallejo : Kaiser Permanente Oncology Clinical Trials

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Vallejo :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Walnut Creek :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Colorado

Aurora : University of Colorado Cancer Center

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Denver : Eastern Colorado Health Care System - Denver VA

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Denver : Rocky Mountain Cancer Centers

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Denver :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Denver :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Grand Junction : Saint Mary's Regional Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Grand Junction : St. Mary's Hospital Regional Cancer Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Wheat Ridge : Mountain Blue Cancer Care Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Connecticut

Bridgeport : Gastroenterology Associates of Fairfield County

Head to Head Study Epi proColon and FIT

Middletown : Middlesex Hospital Cancer Center

Head to Head Study Epi proColon and FIT

New Haven :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

New Haven : Yale Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Stamford : Stamford Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

View More »

Stamford : Hematology Oncology Associates, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Stamford : The Stamford Hospital

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Trumbull :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Delaware

Newark : Christiana Care Health Services

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

District of Columbia

Washington : George Washington University - Medical Faculty Associates

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Washington : Georgetown University

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Washington : Georgetown University Medical Center

Lapatinib and Cetuximab in Patients With Solid Tumors

Washington : Georgetown University

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Washington : Georgetown Lombardi Comprehensive Cancer Center

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Washington : Georgetown Lombardi Comprehensive Cancer Center

PD-0332991, 5-FU, and Oxaliplatin for Advanced Colorectal Cancer

Florida

Jacksonville : Integrated Community Oncology Network

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Miami : Advanced Medical Specialties

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

New Port Richey : Pasco Pinellas Cancer Center

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Boynton Beach : University Cancer Institute

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Boyton Beach : Zasa Clinical Research

Head to Head Study Epi proColon and FIT

Fort Lauderdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fort Myers :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Ft. Myers : Florida Cancer Specialists

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Gainesville : University of Florida, Davis Cancer Center (VA)

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Gainesville : Florida Cancer Specialists

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Hollywood : Center for Gastrointestinal Disorders

Head to Head Study Epi proColon and FIT

Hollywood :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Jacksonville : Mayo Clinic Florida Hematology/Oncology

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Jacksonville :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Miami : Advance Medical Research Service Corp.

Head to Head Study Epi proColon and FIT

Miami :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Miami Beach : Research Site

A Phase 1 Study to Evaluate MEDI4736

Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Orange City : Compass Research, LLC

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Orlando : Florida Hospital Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Orlando :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Orlando : MD Anderson Cancer Center Orlando

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Port Orange : Accord Clinical Research, LLC

Head to Head Study Epi proColon and FIT

Port St Lucie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Port St. Lucie : Hematology Oncology Associates of the Treasure Coast

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Rockledge : Cancer Care Centers of Brevard

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

St. Petersburg : Florida Cancer Specialists

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Tampa : Research Site

A Phase 1 Study to Evaluate MEDI4736

Tampa : Stedman Clinical Trials, LLC

Head to Head Study Epi proColon and FIT

Tampa : H. Lee Moffitt Cancer Center (Moffitt Cancer Center)

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Titusville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Weston : Cleveland Clinic Florida

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Georgia

Atlanta : Peachtree Hematology and Oncology Consultants, PC

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Atlanta : Peachtree Hematology Oncology Consultants, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Atlanta :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Augusta : Research Site

A Phase 1 Study to Evaluate MEDI4736

Augusta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Gainesville : Northeast Georgia Medical Center

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Lawrenceville : Suburban Hematology Oncology Associates, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Lawrenceville : Suburban Hematology-Oncology Assoc., PC

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Macon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Hawaii

Honolulu : Queen's Medical Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Honolulu : University of Hawaii

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Honolulu : Kaiser Foundation Hospitals

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Honolulu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Illinois

Arlington Heights : Cancer Care & Hematology Specialists of Chicagoland

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Berwyn : Vanguard Health

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Centralia : University Hematology Oncology, Inc

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Chicago : Northwestern University

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Chicago : Hematology/Oncology Associates

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

View More »

Chicago : Northwestern University, Northwestern Medical Faculty Foundation

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Chicago : Northwestern University

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Chicago : The University of Chicago Medical Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Chicago : University of Illinois at Chicago

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Chicago : Weiss Memorial Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Chicago :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Chicago : Jesse Brown VA

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Chicago : Rush University Gastroenterologists

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Chicago : Stroger Cook County

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Chicago : University of Illinois at Chicago

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Galesburg : Medical and Surgical Specialists

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Galesburg : Medical and Surgical Specialists

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Harvey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Harvey : Ingalls Memorial Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Harvey :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Harvey : Ingalls Cancer Research Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Joliet : Joliet Oncology-Hematology Associates, Ltd.

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Joliet :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Maywood :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Park Ridge : Oncology Specialists,S.C. Center for Advanced Care

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Peoria : Illinios Cancer Care

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Peoria : Illinois CancerCare, P.C.

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Peoria :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Peoria : Illinois Cancer Care, P.C.

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Skokie : Edward Kaplan and Associates

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Springfield : Springfield Clinic

Head to Head Study Epi proColon and FIT

Urbana : Carle Cancer Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Warrenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Zion : Midwestern Regional Medical Center

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

Indiana

Goshen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Goshen :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Indianapolis : Investigative Clinical Research of Indiana, LLC

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Indianapolis : Indiana University Simon Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

View More »

Indianapolis : Indiana University Simon Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Lafayette : Horizon Oncology Research, Inc.

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Muncie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Terre Haute : Providence Medical Group

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Terre Haute : Providence Medical Group

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Terre Haute :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Iowa

Clive : Medical Oncology & Hematology Associates (Clinic #3)

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Des Moines : Iowa Oncology Research Association

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Des Moines : Medical Oncology & Hematology Associates (Clinic #2)

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Des Moines : Medical Oncology & Hematology Associates (Clinic #1)

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Sioux City : Siouxland Hematology-Oncology Associates, LLP

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Kansas

Wichita : Cancer Center of Kansas

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Kentucky

Lexington : Central Baptist Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Louisville : Owsley Brown Frazier Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Louisville : University of Louisville

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Louisville :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Louisville : Louisville Oncology

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

View More »

Louisville :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Louisville : University of Louisville/James Brown Cancer Center

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Paducah :

A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Louisiana

Baton Rouge : Gastroenterology Associates

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Baton Rouge : Mary Bird Perkins Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Metairie : New Orleans Research Institute

Head to Head Study Epi proColon and FIT

Shreveport : Louisiana Research Center

Head to Head Study Epi proColon and FIT

Maine

Scarborough : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Scarborough :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Maryland

Bethesda : Center for Cancer and Blood Disorders

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Baltimore : University of Maryland Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Baltimore : John Hopkins University

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Baltimore : Weinberg Cancer Institute at Franklin Square

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Bethesda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Bethesda :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Bethesda : National Capital Clinical Research Consortium

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Bethesda : Center for Cancer and Blood Disorders

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Chevy Chase : Metropolitan Gastroenterology Group

Head to Head Study Epi proColon and FIT

Chevy Chase : Chevy Chase Clinical Research

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Glen Burnie : Greenbaum Cancer Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Rockville : Associates of Oncology Hematology, P.C.

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Rockville :

A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Massachusetts

Boston : Tufts Medical Center

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Boston :

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Boston : Dana Farber Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Boston : Dana-Farber Cancer Institute

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Boston : Massachusetts General Hospital

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Brockton : Commonwealth Clinical Trials

Head to Head Study Epi proColon and FIT

Brockton : Commonwealth Clinical Studies

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Burlington : Lahey Clinic

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Michigan

Detroit : Karmanos Cancer Institute

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Ann Arbor : University of Michigan Hospital and Health Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Ann Arbor : University of Michigan Comprehensive Cancer Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Ann Arbor : St. Joseph Mercy Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Ann Arbor : St. Joseph Mercy Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Detroit : Henry Ford Hospital

Association Between Hepatitis C Infection and Renal Cell Carcinoma

Detroit : Henry Ford Health System

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Detroit : Barbara Ann Karmanos Cancer Institute

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Detroit :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Detroit : Henry Ford Health System

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Grand Rapids : Grand Rapids Clinical Oncology Program

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Kalamazoo : West Michigan Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Royal Oak : William Beaumont Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Royal Oak : Beaumont Hospital

Head to Head Study Epi proColon and FIT

Troy : Troy Gastroenterology PC Center for Digestive Health

Head to Head Study Epi proColon and FIT

Minnesota

Duluth : Essentia Health Duluth CCOP

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Minneapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Minneapolis : Virginia Piper Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Minneapolis : Virginia Piper Cancer Institute

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Minneapolis : University of Minnesota

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

View More »

Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rochester : Mayo Clinic

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Saint Louis Park : Regions Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Saint Louis Park : St. John's Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Saint Louis Park : Metro Minnesota CCOP

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

St Louis Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

St. Cloud : Coborn Cancer Center/ CentraCare Health Plaza

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Mississippi

Tupelo : Hematology and Oncology Associates at BridgePoint

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Missouri

Bridgeton : Saint Louis Cancer Care LLP

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Bridgeton :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Columbia : Ellis Fischel Cancer Center at University of Missouri- Columbia

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Jefferson City : Jefferson City Medical Group

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Kansas City :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Kansas City : Research Medical Center

Head to Head Study Epi proColon and FIT

Kansas City : Saint Luke's Cancer Institute

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Saint Joseph : Saint Joseph Oncology, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Montana

Nebraska

Lincoln : Southeast Nebraska Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Lincoln :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Nevada

Las Vegas : Comprehensive Cancer Centers of Nevada

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Henderson : Comprehensive Cancer Centers of Nevada

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Las Vegas : Comprehensive Cancer Centers of Nevada

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Las Vegas : CCCN

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

New Hampshire

Lebanon : Dartmouth-Hitchcock Medical Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Portsmouth : Portsmouth Regional Hospital

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

New Jersey

Cherry Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Cherry Hill :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Elizabeth : Trinitas Comprehensive Cancer Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Hackensack : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Morristown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Morristown :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Morristown : Hematology-Oncology Associates of Northern NJ

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Teaneck : Holy Name Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

New Mexico

Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Albuquerque :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Farmington :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Las Cruces :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Santa Fe :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

New York

Bronx : Biomedical Research Alliance of New York

Metastatic Colorectal Carcinoma

View More »

Binghampton : Binghampton Gastroenterology Associates

Head to Head Study Epi proColon and FIT

Bronx : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Bronx : Montefiore Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Cooperstown : Bassett Healthcare Center

Head to Head Study Epi proColon and FIT

Great Neck : Long Island Gastrointestinal Group

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Hudson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Jamaica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Lake Success :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

New Windsor : Mid Hudson Medical Research, PLLC

Head to Head Study Epi proColon and FIT

New York : Memorial Sloan Kettering Cancer Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

New York : NYU Cancer Institute

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

New York : Beth Israel Comprehensive Cancer Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

New York : New York Gastroenterology Associates, LLP

Head to Head Study Epi proColon and FIT

New York : Montefiore - Einstein Cancer Care Center

Head to Head Study Epi proColon and FIT

New York : Mount Sinai Medical Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

New York : Mount Sinai School of Medicine

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

New York :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Syracuse : Research Foundation of State University of New York

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

North Carolina

Asheville : Asheville Gastroenterology Associates

Head to Head Study Epi proColon and FIT

Asheville : Asheville Gastroenterology

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Burlington : Alamance Regional Medical Center Cancer Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Chapel Hill :

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Chapel Hill : University of North Carolina at Chapel Hill

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

View More »

Charlotte : Carolinas Hematology-Oncology Associates

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Carolinas Hematology-Oncology Associates - Ballantyne

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Carolinas Hematology-Oncology Associates - University

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Levine Cancer Institute

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Mecklenburg Medical Group - Morehead

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Mecklenburg Medical Group - South Park

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Carolinas Hematology-Oncology - Ballantyne

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Carolinas Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Levine Cancer Institute - Blumenthal Cancer Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Mecklenburg Medical Group

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Mecklenburg Medical Group - Pineville

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Charlotte : Presbyterian Hospital Cancer Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Concord : Northeast Oncology Associates

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Durham : Duke University Medical Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Durham :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Greensboro :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

High Point : Emerywood Hematology and Oncology

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

High Point :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Monroe : Mecklenburg Medical Group - Carolinas Cancer Associates

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Winston Salem : Piedmont Hematology Oncology Associates PA

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Winston-Salem : Digestive Health Specialists, PA

Head to Head Study Epi proColon and FIT

Winston-Salem : Piedmont Medical Research Associates, LLC

Head to Head Study Epi proColon and FIT

Winston-salem :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

North Dakota

Bismarck : Legacy Pharma Research

Metastatic Colorectal Cancer with wild-type KRAS tumors.

View More »

Bismarck : Medcenter One

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Fargo : Lillestol Research, LLC

Head to Head Study Epi proColon and FIT

Grand Forks : Altru Health Systems

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ohio

Canton : Tri Country Hematology / Oncology

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Canton : Gabrail Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Cincinatti : Oncology Hematology Care, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Cincinnati :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

View More »

Cincinnati : Oncology Hematology Care, Inc

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Cincinnati : Gastroenterology Research Consultants of Greater Cincinnati

Head to Head Study Epi proColon and FIT

Cincinnati : TriHealth Oncology Institute/Oncology Partners Network

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Columbus :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Middletown : Signal Point Clinical Research Center, LLC

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Middletown : Signal Point Clinical Research Center, LLC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Sylvania : Hickman Cancer Center at Flower Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Toledo :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Toledo : Mercy Cancer Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Toledo :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Toledo : Toledo Community Oncology Program- Toledo Community Hospital

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Wilmington : Oncology Hematology Care, Inc.

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Oklahoma

Oklahoma City :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Oklahoma City :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Tulsa : Cancer Care Associates

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Oregon

Tualatin : Northwest Cancer Specialists

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Bend : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Bend : Bend Memorial Clinic

Head to Head Study Epi proColon and FIT

Portland : Oregon Health and Science University

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Portland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Portland : Kaiser Permanente Northwest Region Oncology Hematology

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Portland : Northwest Gastroenterology Clinic, LLC

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Portland : Providence Portland Medical Center

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Pennsylvania

Philadelphia : University of Pennsylvania

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Philadelphia : University of Pennsylvania

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Abington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Beaver : UPMC Cancer Center Beaver

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bethlehem : St. Luke's Hospital and Health Network

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Camp Hill : PinnacleHealth

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Dunmore :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Greensburg : UPMC Cancer Center Arnold Palmer at Mountain View

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Harrisburg : Pinnacle Health

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Kingston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Media :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Philadelphia : Fox Chase Cancer Center

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Philadelphia :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Pittsburgh : UPMC Hillman Cancer Center

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Pittsburgh : UPMC Hillman Cancer Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Pittsburgh : University of Pittsburgh Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Pittsburgh : UPMC Cancer Center Passavant

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Uniontown : UPMC Cancer Center Uniontown

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Willow Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rhode Island

East Providence : Pharma Resource

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Providence : The Miriam Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Providence : Rhode Island Hospital

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

South Carolina

Charleston : Medical University of South Carolina

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Charleston : Charleston Hematology Oncology Associates

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Columbia : South Carolina Oncology Associates

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Columbia :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Mt. Pleasant : Coastal Carolina Research Center

Head to Head Study Epi proColon and FIT

Tennessee

Chattanooga :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Chattanooga : Chattanooga Oncology Hematology Associates

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Collierville : Family Cancer Center

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Germantown : Gastro One

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Germantown : The Jones Clinic

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

View More »

Kingsport : Gastroenterology Associates

Head to Head Study Epi proColon and FIT

Knoxville : Center for Biomedical Research

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Knoxville : Center for Biomedical Research - Oncology

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Knoxville : Tennessee Cancer Specialists

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Nashville : Tennessee Oncology

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Nashville : Tennessee Oncology, PLLC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Nashville :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Nashville : Tennessee Oncology, PLLC

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Nashville :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Nashville : Sarah Cannon Research Institute

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Texas

Dallas : Mary Crowley Cancer Research Center

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Dallas : Texas Oncology - Baylor - Charles A. Sammons Cancer Center

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Fort Worth : Texas Oncology - Fort Worth

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Round Rock : Texas Oncology - Seton Williamson

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Abilene : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Arlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Beaumont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Bedford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Carrolton : Independent Clinical Research, LLC

Head to Head Study Epi proColon and FIT

Corpus Christi :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Dallas : University of Texas Southwestern Medical Center at Dallas

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Dallas : Mary Crowley Cancer Research Center

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Denton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Flower Mound : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fort Worth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fort Worth : Center for Cancer and Blood Disorders, PC

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Fort Worth :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Fort Worth : The Center for Cancer and Blood Disorders

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Ft. Worth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Garland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Houston : UT MD Anderson Cancer Center

4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis

Houston : UT MD Anderson Cancer Center

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Houston : UT MD Anderson Cancer Center

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Houston : UT MD Anderson Cancer Center

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Houston :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Lubbock : Joe Arrington Cancer Research and Treatment Center

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Mcallen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Odessa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Round Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

San Antonio : South Texas Oncology and Hematology, PA

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

San Antonio :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Sherman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Sugar Land : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Temple : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tyler : Digestive Health Specialists

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Waco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Weatherford : The Center for Cancer and Blood Disorders

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Webster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Wichita Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Utah

Bountiful : Utah Cancer Specialists - Bountiful/Lakeview Office

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Layton : Utah Cancer Specialists - Layton/Davis Office

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Murray : Utah Cancer Specialists - Cottonwood Office

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ogden : Northern Utah Associates

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Ogden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Provo : Utah Cancer Specialists - Provo Office

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Salt Lake City :

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Salt Lake City : Utah Cancer Specialists

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Salt Lake City : Utah Cancer Specialists

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Salt Lake City : Utah Cancer Specialists - Salt Lake Clinic

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Salt Lake City : Utah Cancer Specialists - Salt Lake Regional

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Salt Lake City : St. Mark's Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Salt Lake City : Salt Lake Research

Head to Head Study Epi proColon and FIT

Salt Lake City : Huntsman Cancer Institute

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

Salt Lake City : Utah Cancer Specialists

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

West Jordan : Utah Cancer Specialists - Jordan Valley

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Virginia

Fairfax : Virginia Cancer Specialists

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Newport News : Peninsula Cancer Institute

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Newport News : Virginia Oncology Associates

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Roanoke : Oncology and Hematology Associates of SW Virginia, Inc, DBA Blue Ridge Cancer Care

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Chesapeake : Gastroenterology Associates of Tidewater

Head to Head Study Epi proColon and FIT

Fairfax : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fredericksburg : Hematology/Oncology Associates of Fredericksburg

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Midlothian : Virginia Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Newport News : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Norfolk : Clinical Research Associates of Tidewater

Head to Head Study Epi proColon and FIT

Norfolk : Digestive and Liver Disease Specialists

Head to Head Study Epi proColon and FIT

Norfolk : Digestive and Liver Disease Specialists

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Richmond : Virginia Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Richmond : Virginia Piper Cancer Institute

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Richmond :

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Winchester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Washington

Kennewick : Columbia Basin Hematology and Oncology

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Spokane : Medical Oncology Associates

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Tacoma : MultiCare Health System

Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer

View More »

Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Seattle : University of Washington

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Spokane : Evergreen Hematology and Oncology

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Wisconsin

Green Bay : St. Mary's Hospital / Green Bay Oncology

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Green Bay : St. Vincent Hospital / Green Bay Oncology

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Madison : Dean Foundation Medical Research

Head to Head Study Epi proColon and FIT

Madison : University of Wisconsin

Head to Head Study Epi proColon and FIT

Madison :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

View More »

Milwaukee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Milwaukee : Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Milwaukee : Aurora St. Luke's Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Wauwatosa :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Argentina

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Caba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Santa Fe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tucumain : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Viedma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Australia

Adelaide : Royal Adelaide Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Adelaide : The Queen Elizabeth Hospital

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

Ballarat : Ballarat Health Services

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Bedford Park : Flinders Medical Centre

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Bedford Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Bedford Park : Flinders Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Brisbane :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Camperdown :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Concord : Concord Repatriation General Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Darlinghurst :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Darlinghurst : St. Vincent's Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

East Bentleigh : Monash Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Elizabeth Vale : Lyell McEwin Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Footscray : Western Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Frankston : Peninsula Oncology Centre

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Frankston : Peninsula Oncology Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Heidelberg :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Heidelberg : Austin Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Herston : Royal Brisbane and Women's Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Hobart : Royal Hobart Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Hobart : Royal Hobart Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Kogarah : St George Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Launceston :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Liverpool : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Malvern : Cabrini Hospital Malvern

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Murdoch :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Nedlands : Sir Charles Gairdner Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Nedlands : Hollywood Private Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Noble Park : South Eastern Private

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

North Adelaide :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Parkville : The Royal Melbourne Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Perth : Mount Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Perth : Royal Perth Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Port Macquarie :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Prahran : Alfred Health

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Randwick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Ringwood : Ringwood/Knox Private

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ringwood East : Maroondah Public

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Southport : Gold Coast Health Service District

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

St Leonards :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

St Leonards : Royal North Shore Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

St. Leonards : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Subiaco :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Sydney : Royal North Shore Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Townsville :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Tweed Heads : Tweed Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Wahroonga :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Waratah : Calvary Mater Newcastle

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Westmead : Westmead Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Woden :

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Wodonga : Border Medical Oncology

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Wodonga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Wollongong : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Woodville South : Queen Elizabeth II Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Woodville South : The Queen Elisabeth Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Woolloongabba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Woolloongabba : Princess Alexandra Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Austria

Graz : Medizinische Universitat Graz

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Graz : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Innsbruck : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Innsbruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Krems : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Linz : Krankenhaus der Barmherzigen Schwestern Linz

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Ried : Hospital BHS Ried

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

Salzburg : Salzburger Landesklinken

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Salzburg : Landeskrankenhaus Salzburg, Univ. Klinik für innere Medizin III, Universitätsklinikum der PMU

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

St Poelten : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Vienna : KH BHB Vienna

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

Vienna : Med. Univ. Vienna, General Hospital Vienna

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Vienna : 5th Med., Clinic Hietzing

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Vienna : University Vienna

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Wels : Klinikum Wels-Grieskirchen GmbH

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Wels : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wels : Klinikum Wels-Grieskirchen GmbH

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Wien : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wien : Wilhelminenspital Wien

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Wien : Universitaetsklinik fur Innere Medizin

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Belgium

Aalst :

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin

Aalst :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Aalst : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aalst : OL Vrouw Ziekenhuis Aalst Gastro-Enterologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Antwerp : Antwerp University Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

View More »

Antwerpen : Ziekenhuisnetwerk Antwerpen - AZ Middelheim

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Antwerpen :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Antwerpen : ZNA Middelheim

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Assebroek :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Bonheiden : Imelda VZW

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Bonheiden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Bonheiden :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Bonheiden : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bonheiden : Imelda Ziekenhuis

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Bonheiden : Imelda Ziekenhuis GI Clinical Research Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bornem :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Bornem : Sint-Josef Ziekenhuie (Campus Bornem)

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Brasschaat :

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin

Brasschaat :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Brasschaat : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brugge : AZ Sint-Lucas Brugge

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Brugge :

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin

Brugge :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Brugge : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Brussels : Cliniques Universitaires St Luc

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Brussels : Erasme Hospital

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Brussels : Institut Jules Bordet - Centre de Tumeurs d'ULB

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Brussels : Cliniques Universitaires UCL St. Luc

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Bruxelles :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Charleroi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Charleroi : Grand Hospital de Charleroi

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Dendermonde :

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin

Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Edegem : Antwerp University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Eupen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gent :

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin

Gent :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Gent : UZ Gent

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Gent : AZ Middelares Gent

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Gent : Universiteits Ziekenhuis Gent

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Gent : AZ Maria Middelares

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Gent : University Hospital Gent

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Gilly : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Haine-saint-paul :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Haine-Saint-Paul : Hospital de Jolimont

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Haine-St.- Paul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Hasselt :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Hornu :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Ieper :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Kortrijk : AZ Groeninge - Campus Sint-Niklaas

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Kortrijk :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Leuven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Leuven :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Leuven : UZ Gasthuisberg

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Leuven : University Hospital, Gasthuisberg

Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27

Leuven : UZ Leuven, Campus Gasthuisberg

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Leuven : Leuven University Hospital - Campus Gasthuiseberg

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Liege :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Liege : Centre Hospitalier Universitaire de Liege

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Lier :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Mechelen :

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin

Mechelen :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Mechelen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Mechelen : AZ Sint Maarten Mechelen/Duffel

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Mechelen : VZW Emmaus St. Maarten Ziekenhuis Mechelen and St. Marten Ziekenhuis Duffel

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Mons :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Mons :

Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)

Namur : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oostende :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Oostende : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oudenaarde :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Reet : AZ Heilige Familie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Roeselare :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Ronse :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Seraing :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Sint-niklaas :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Sint-Niklaas : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Tongeren :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Turnhout :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Verviers :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Verviers : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wilrijk :

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin

Wilrijk :

An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)

Wilrijk : Sint-Augustinus Ziekenhuis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Brazil

Ijui : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Salvador : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Sao Jose Do Rio Preto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Canada

Barrie : Royal Victoria Regional Health Centre

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Edmonton : Cross Cancer Institute

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Greenfield Park : Hôpital Charles-LeMoyne

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Laval : Cité de la Santé de Laval

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

London : London Health Sciences Centre

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Montreal : Maisonneuve-Rosemont Hospital Research Centre

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Sudbury : Northeast Cancer Centre of Health Sciences North, Health Sciences North

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Thunder Bay : Thunder Bay Regional Health Sciences Centre

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

Vancouver : British Columbia Cancer Agency - Vancouver Centre

Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.

View More »

Calgary : University of Calgary

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Calgary : Tom Baker Cancer Centre

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Edmonton :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Greenfield Park : CSSS Champlain - Charles-Lemoyne Hospital

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

Halifax : QEII Health Services Centre

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Laval : Hopital De La Cite-De-La-Sante

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Levis : CSSS Alphonse-Desjardins (CHAU Hotel-Dieu de Levis)

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

London : London Regional Cancer Program

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Montreal : Hopital Saint-Luc - Pavillon Principal

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Montreal : McGill University Health Centre

Multimodal Prehabilitation for Colorectal Surgery

Montreal : Montreal General Hospital

Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity

Montreal : CHUM-St. Luc Hospital

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

Montreal : Jewish General Hospital

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

Ottawa : Ottawa Health Research Institute - General Division

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Quebec : Hotel-Dieu de Quebec

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

Sherbrooke : CHUS-Centre de recherche Etienne-Le Bel

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

St-Jérome : CSSS St-Jérome

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

Toronto : Novartis Investigative Site

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Vancouver : British Columbia Cancer Agency

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

China

Beijing :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Beijing : Peking University, People's Hospital

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

Beijing : Peking University, School of Oncology

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

Changzhou :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Chengdu :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

View More »

Fuzhou :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Guangzhou :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Hang Zhou :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Hangzhou :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Harbin :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Jiangsu :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Jinan :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Nanjing :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Shanghai :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Shanghai : Fudan University cancer hospital

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer

Shenyang :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Wuhan :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Xian City :

An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer

Czech Republic

Denmark

Estonia

Tallinn :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Tartu :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Finland

France

Agen :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Aix En Provence :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Aix en Provence : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aix en Provence cedex 01 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Albi :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

View More »

Alencon :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Amiens :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Amiens : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amilly :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Amily :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Angers :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Arras :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Auch :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Avignon :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bastia :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bayonne : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Beauvais :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Besançon Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Besancon :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Besancon : CHU de Becançon

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Besancon Cedex :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bethune :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Beziers :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bobigny :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bordeaux : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Bordeaux :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bordeaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bordeaux : CHU de Bordeau

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Boulogne Sur Mer :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bourg En Bresse :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Bourg en Bresse : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Briis Sous Forges :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Brive La Gaillarde :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Brive la Gaillarde : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Caluire Et Cuire :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Cannes :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Carcassonne :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Castelnau Lez :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Challes Les Eaux :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Champigny Sur Marne :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Chateauroux :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Clermont-ferrand :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Colmar :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Colmar Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Compiegne :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Creil :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Creteil :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Creteil : AERO

Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy

DAX :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Dijon :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Dijon : Centre Georges François Leclerc

Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Capecitabine Plus Mitomycin

Dijon cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dreux :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Dunkerque :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Evreux :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Flers :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Frejus :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

GAP :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Gien :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Gonesse :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Hayange :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Hyeres :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

La Chaussee Saint Victor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

La Chaussee St Victor :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

La Roche Sur Yon :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

La Rochelle :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

La Seyne Sur Mer : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

La Tronche :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

La Tronche : Hospitalier Universitaire de Grenoble C.H.U.

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Lagny-sur-marne :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Le Mans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Le Mans Cedex 9 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lille :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Longjumeau :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Longjumeau : Centre Hospitalier General de Longjumeau

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Longjumeau cedex 1 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lormont :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Lyon :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Mainvilliers :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Marseille :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Marseille : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Metz :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Metz Tessy :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Mont de Marsan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Montauban :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Montbeliard :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Mont-de-marsan :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Montelimar :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Montfermeil :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Montivilliers :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Montpellier :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Montpellier : CRLC Val d'Aurelle

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Mougins :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Muret :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Nancy :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Nancy : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Narbonne :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Neuilly-sur-seine :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Nevers :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Nice :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Nice : Hopital de l'Archet II, CHU de Nice

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Nimes :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Nogent Sur Marne :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Orléans : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Orleans :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Osny :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Périgueux cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Paris :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Paris : Hospital European Georges Pompidou

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Paris Cedex 20 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Perigueux :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Perpignan :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Pessac :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Pierre Benite :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Poitiers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Pontoise Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Pringy Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rambouillet :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Rang Du Fliers :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Reims : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rennes Cedex : Centre Eugène Marquis

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Rennes Cedex : Centre Eugene Marquis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Rouen :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Rouen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Brieuc :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Saint Grégoire cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Jean :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Saint Quentin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Selestat :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Soissons Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soyaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

St Gregoire :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

St Lo :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

St Malo :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

St Martin Boulogne :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

St Quentin :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Strasbourg :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Strasbourg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Thonon-les-bains :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Toulouse :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Valence :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Vannes :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Venissieux :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Verdun :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Versailles :

An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)

Vichy cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villefranche Sur Saone Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif : Institut Gustave-Roussy

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Germany

Altstadt : Internistische Gemeinschaftspraxis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Aschaffenburg : Klinikum Aschaffenburg

A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)

Augsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Augsburg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Balingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Bamberg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Berlin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Berlin : Charite Campus Virchow Klinikum

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bochum : Augusta Clinic

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Bonn : Johanniterkrankenhaus Bonn

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bonn : Universitaetsklinikum Bonn

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bonn : Braxiskooperation Bonn, Fachartze fur Innere Medizin

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Bremerhaven : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Essen : Kliniken Essen Mitte

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Essen : Gemeinschaftspraxis Hamatologie und internistische Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Frankfurt : Universitat Frankfurt Institute fur Diagnostic und Interventionelle Radiologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Frankfurt/Main : Krankenhaus Nordwest

Vaccination Against MSI Colorectal Cancer

Freiburg : iOMEDICO AG

Colorectal Cancer Registry

Fulda : MVZ Fulda

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Goslar : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Halle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Halle (Saale) : University Clinic - Internal Medicine I

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Halle/Saale : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Hamburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Hamburg : Asklepios Klinik Altona, Abt. Radiologie, Neuroradiologie, Nuklearmedizin

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Hamburg : Universitastsklinikum Saarland

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Herdecke : Hospital Herdecke, private University

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Holzkirch : Praxisgemeinschaft Dr. med. Peter Sandor und Peter Kohl

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ingolstadt : Onklogische Praxis Dr. Gerald Gehbauer

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Köln : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Karlsruhe : Klinikum Karlsruhe, Stadtisches Klinikum Karlsruhe, Zentralinstitut fur Bildgebende Diagnostik

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Karlsruhe : Studienzentrale, St. Vicentius Kliniken gAG-Studienzentrale

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Kassel : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lübeck : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Magdeburg : Schwerpunktpraxis fur Hamatologie und Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Magdeburg : Klinikum Magdeburg GmbH, Klinik für Hämatologie/Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Magdeburg : Universitaetsklinikum Magdeburg

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Magdeburg : Clinic for Radiology and Nuclear Medicine

Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy

Magdeburg : Clinic for Radiology and Nuclear Medicine

Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity

Mannheim : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marburg : Universitatsklinikum GieBen und Marburg

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Mönchengladbach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Muenchen : Klinikum Bogenhausen

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Muenchen : Klinikum der Universitaet Muenchen

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Munchen : Klinikum rechts der Isar der TU Munchen

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Munchen : Schwerpunktspraxis fur Hamatologie und Internistische Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Munchen : Hamato-Onkologische Schwerpunktspraxis

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Munich : Med. Clinic III, University Munich, Grosshadern

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Munich : Ludwig-Maximilians - University of Munich

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Neunkirchen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rotenburg (Wümme) : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soest : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soest : Clinic Kloster Paradiese

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Stralsund : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Ulm : Med 1, University Clinic Ulm

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

Velbert : Praxis fur Hamatologie und Internnistische Onkologie

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Würselen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Weiden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Weilheim : Schwerpunktspraxis und Tagesklinik Dr. Perker/Dr. Sandherr

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Greece

Hungary

Budapest : Orszagos Onkologiai Intezet

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Budapest :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Debrecen :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Gyor : Petz Aladar Megyei Oktato Korhaz

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

View More »

Gyor :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Gyula : Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Gyula :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Kaposvar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kecskemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kecskemet :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Kistarcsa :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Miskolc :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

National Institute Oncology : Medical Center of the University of Pecs

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Nyíregyháza :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Salgótarján :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Szeged :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Szekesfehervar :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Szekszard :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Szombathely :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Tatabanuya :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Veszprem :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Zalaegerszeg :

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

India

Ahmedabad : Hemato-Oncology Clinic Ahmedabad PVT. Ltd Vedanta

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kochin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kolkata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kolkata : Chittaranjan National Cancer Institute

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

View More »

Kolkata : B.P.Poddar Hospital and Medical Research Ltd.

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Mumbai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Mumbai : Shatabdi Superspeciality Hospital

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

New Delhi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Trivandrum : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Ireland

Cork : Bon Secours Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Dublin : St. Vincent's University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Israel

Beer Sheva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Haifa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Haifa : Rambam Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Haifa : Elisha Hospital

Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy

Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Jerusalem : Shaare-Zedek Medical Centre

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Netanya : Laniado Hospital

Performance Evaluation of the NaviAid™ G-Eye System

Petah Tikva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Petah Tiqva : Rabin Medical Center, Beilinson Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Ramat Gan : Sheba Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Tel Aviv : TA Sourasky Medical Center

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tel-Aviv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Italy

Albano Laziale :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Ancona : Az Osp. Univ. Ospedali Riuniti 'Umberto I G.M Lancisi G.Salesi'

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Ancona :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Benevento :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Biella :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

View More »

Bologna :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Bologna : A.O.U. die Bologna

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Brescia :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Brescia : Fondazione Poliambulanza

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Brindisi :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Candiolo : Fondazione del Piemonte per I'Oncologia IRCC

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Castellana Grotte (ba) :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Catania :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Catania :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Cefalù PA : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Cefalu :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Chieti :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Como :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Cosenza :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Cremona :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Cuneo :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Este :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Este (pd) :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Fano :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Ferrara :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Foggia :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Genova : IRCCS Azienda Ospedaliera Universitaria San Martino - Istituto Nazionale per la Ricerca sul Cancro

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Genova : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Genova :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Genova : Universita Delgi Studi de Genova (UNIGE)- Azienda Ospedaliera. Universitaria "San Martino" (Ospedale San Martino)

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Grosseto :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Imola (bo) :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

La Spezia :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Lamezia Terme (cz) :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

L'aquila :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Lecce :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Lecco :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Lido Di Camaiore :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Livorno :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Macerata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Macerata :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Messina :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Milan : A.O. Ospedale Niguarda Ca' Granda

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Milano :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Milano :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Mirano (ve) :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Modena :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Modena :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Montecchio Maggiore :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Monza :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Napoli :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Napoli :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Napoli : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Napoli : Seconda Università degli Studi di Napoli

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Novara :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Orbassano :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Orbassano : AOU San Luidi di Orbassano

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Padova : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Padova :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Padova : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Parma :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Pavia :

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer

Pavia :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Perugia :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Pisa : Azienda Ospedaliero

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Pontedera :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Pordenone :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Reggio Calabria :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Reggio Emilia : Arcispedale Santa Maria Nuova

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Reggio Emilia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rionero in Vulture :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Roma :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Roma : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Rovigo :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Rozzano (MI) : Istituto Clinico Humanitas

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

San Giovanni Rotondo :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Saronno :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Sassari :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Savona :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Siena :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Sondrio : Ospedale di Sondrio

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Sora :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Taormina :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Teramo :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Torino :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Torino : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Treviso :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Varese :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Vimercate :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Viterbo :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Japan

Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Chiba : Chiba Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Chuo-ku : National Cancer Center Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Ehime : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Fukuoka : National Hospital Organization Kyushu Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Gifu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kashiwa : National Cancer Center Hospital East

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Kita-adachi-gun : Saitama Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Kobe : Kobe City Medical Center General Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Kochi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Koto-ku : The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Kumamoto : Kumamoto University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Matsuyama : National Hospital Organization Shikoku Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Nagoya : Aichi Cancer Center Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Oita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Osaka : Osaka Medical Center for Cancer and Cardiovascular Diseases

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Sapporo : KKR Sapporo Medical Center TONAN-Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Sapporo : Hokkaido University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Shimotsuke : Jichi Medical University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Shinjuku-ku : Keio University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Shizuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Sunto-gun : Shizuoka Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Takatsuki : Osaka Medical College Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Tochigi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tokushima : Tokushima University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Tsukuba : Tsukuba University Hospital

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Yokohama : Kanagawa Cancer Center

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Korea, Republic of

Anyang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Goyang-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Incheon : Inha University Hospital

Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer

Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Lebanon

Beirut :

An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

Dora :

An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

El Chouf :

An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

El- Metn :

An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

Jbeil :

An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

View More »

Saida :

An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

Tripoli :

An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

Netherlands

Amstelveen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amsterdam : Novartis Investigative Site

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Breda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Den Haag : HagaZiekenhuis

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Deventer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Dordrecht : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Eindhoven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Enschede : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Groningen : Universitair Medisch Centrum Groningen

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Groningen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Leiden : LUMC

Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study

Leiderdorp : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Purmerend : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Roosendaal : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rotterdam : Erasmus MC

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Sittard - Geleen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Utrecht : Universitair Medisch Centrum Utrecht

Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer

Utrecht : UMC Utrecht

Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study

Vlissingen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Zutphen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

New Zealand

Auckland : University of Auckland

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Christchurch : Christchurch Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Dunedin : Dunedin Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Newtown : Wellington Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Palmerston : Palmerston North Hospital

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Norway

Oslo :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Poland

Bialystok : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gdansk : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Koszalin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Krakow : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lubin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Olsztyn : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Poznan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Walbrzych : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Warsaw : Wojskowy Instytut Medyczny (WIM)

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Warszawa : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wroclaw : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Portugal

Puerto Rico

Romania

Alba Iulia : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Baia-Mare : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brasov : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucharest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Bucharest :

An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)

View More »

Bucharest :

An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)

Bucharest : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucuresti : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Cluj-Napoca : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Cluj-Napoca : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Iasi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Oradea : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Oradea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Ramnicu Valcea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Targu Mures : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Timisoara : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Serbia

Belgrade :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)

Kragujevac :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)

Kragujevac :

An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)

NIS :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)

Sremska Kamenica :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)

Slovakia

Banska Bystrica :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Banska Bystrica :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Bardejov : St.James Hospital and Clinic

Prevention of Irinotecan Induced Diarrhea by Probiotics

Bratislava :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Bratislava :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

View More »

Bratislava : National Cancer Institute, Slovakia

Prevention of Irinotecan Induced Diarrhea by Probiotics

Bratislava : Oncologic Institute of St.Elisabeth OUSA

Prevention of Irinotecan Induced Diarrhea by Probiotics

Komarno : Zdravspol s r.o. - oncologic ambulance

Prevention of Irinotecan Induced Diarrhea by Probiotics

Kosice :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Kosice :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Košice : National cancer Institute

Prevention of Irinotecan Induced Diarrhea by Probiotics

Martin :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Martin :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Nitra :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Nitra :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Poprad :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Poprad :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Poprad : POKO Poprad Ltd.

Prevention of Irinotecan Induced Diarrhea by Probiotics

Presov :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Presov :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Ruzomberok :

An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer

Ruzomberok :

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Trencin : Faculty Hospital Trencin

Prevention of Irinotecan Induced Diarrhea by Probiotics

Slovenia

Spain

Barcelona : Hospital Vall D'Hebron

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Barcelona : Hospital Universitari Vall d'Hebron

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Barcelona : Institut Català d'Oncologia

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

La Coruna : Centro Oncologico de Galicia

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

View More »

Madrid : Centro Integral Oncologico Clara Campal

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Madrid : Spanish Cooperative Group for Gastrointestinal Tumour Therapy

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Madrid : Spanish Cooperative Group for Gastrointestinal Tumour Therapy

Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer

Madrid : Hospital Universitario Ramon y Cajal

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Oviedo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Pamplona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Pamplona : Clinica Universitaria de Navarra

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Pamplona : Hospital de Navarra, Servicio de Ongoligia, Planta Baja

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Sabadell : Corporacio Sanitaria Parc Tauli

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Sabadell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Santander : Hospital Universitario Marques de Valdecilla

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Santander : Hospital Universitario Marqués de Valdecilla

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Sevilla : Hospital Universitario Virgen del Rocío

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Terrassa : Hospital Mutua de Terrassa

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Valencia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Valencia : Hospital Clinico Universitario De Valencia

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer

Zaragoza : Hospital Universitario Miguel Servet

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Sweden

Switzerland

Aarau :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Basel :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Luzern :

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Zurich : Universitatsspital Zurich

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Taiwan

Kaohsiung : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Kuei Shan Hsiang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Taichung : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Taichung :

An Observational Study of Avastin (Bevacizumab) With First-Line Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

Tainan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

View More »

Taipei : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Second Line Metastatic Colorectal Cancer

Taipei :

An Observational Study of Avastin (Bevacizumab) With First-Line Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

United Kingdom

Aberdeen : Aberdeen Royal Infirmary

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Birmingham :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Bristol :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Cambridge : Addenbrooke's Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Carlisle :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

View More »

Chelsmford :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Dudley :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Edinburgh : Western General Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Glasgow : Beatson West of Scotland Cancer Center

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Ipswich :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Kidderminster :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

London : University College Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Macclesfield :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Maidstone : Maidstone Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Manchester : Christie Hospital

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Manchester : Christie Hospital NHS Foundation Trust

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Northwood, Essex :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Nottingham :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Peterborough : Peterborough and Stamford Hospitals NHS Foundation Trust

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Peterborough :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Romford :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Stafford :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Sutton :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Swindon :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Torquay :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Truro :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Winchester :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Wolverhampton :

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)